AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00256-07v1
51/8/3001    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strahilevitz, J.
Right arrow Articles by Robicsek, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strahilevitz, J.
Right arrow Articles by Robicsek, A.
Antimicrobial Agents and Chemotherapy, August 2007, p. 3001-3003, Vol. 51, No. 8
0066-4804/07/$08.00+0     doi:10.1128/AAC.00256-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Changes in qnr Prevalence and Fluoroquinolone Resistance in Clinical Isolates of Klebsiella pneumoniae and Enterobacter spp. Collected from 1990 to 2005{triangledown}

Jacob Strahilevitz,1* Dalia Engelstein,1 Amos Adler,1 Violeta Temper,1 Allon E. Moses,1 Colin Block,1 and Ari Robicsek2

Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University, Jerusalem 91120, Israel,1 Department of Medicine, Evanston Northwestern Healthcare, 2650 Ridge Ave., Evanston, Illinois 602012

Received 20 February 2007/ Returned for modification 5 April 2007/ Accepted 21 May 2007

Clinical isolates of Klebsiella pneumoniae and Enterobacter spp. collected from 1990 through 2005 at a tertiary care center were studied for qnr genes. Isolates bearing these genes emerged in the mid-1990s, coinciding with the time of a rapid increase in fluoroquinolone resistance. Sixty percent of these isolates were ciprofloxacin susceptible by CLSI breakpoints.


* Corresponding author. Mailing address: Department of Clinical Microbiology and Infectious Diseases, Hadassah Ein-Kerem, Jerusalem 91120, Israel. Phone: 972-50-894 6353. Fax: 972-2-641 9545. E-mail: jstrahilevitz{at}hadassah.org.il

{triangledown} Published ahead of print on 25 May 2007.


Antimicrobial Agents and Chemotherapy, August 2007, p. 3001-3003, Vol. 51, No. 8
0066-4804/07/$08.00+0     doi:10.1128/AAC.00256-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.